Zimmer Biomet price target raised to $132 from $119 at Wells Fargo

Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Zimmer Biomet to $132 from $119 and keeps an Equal Weight rating on the shares. Zimmer reported Q4 sales roughly in line with estimates, but EPS was ahead, and management committed to growing revenues 100-200 basis points above the market, with EPS growing faster than sales growth, the analyst tells investors in a research note.